TCGA-CR-7379-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ANGIOGENESIS+0.390
- MYC_TARGETS_V1+0.350
- TNFA_SIGNALING_VIA_NFKB+0.330
- TGF_BETA_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.280
- MTORC1_SIGNALING+0.280
- UV_RESPONSE_UP+0.270
- KRAS_SIGNALING_UP+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.370
- APICAL_SURFACE-0.220
- BILE_ACID_METABOLISM-0.140
- PEROXISOME-0.090
- SPERMATOGENESIS-0.090
- DNA_REPAIR-0.080
- KRAS_SIGNALING_DN-0.080
- ALLOGRAFT_REJECTION-0.070
- WNT_BETA_CATENIN_SIGNALING-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278862 | — | — | 0.808 |
| 2 | SAMN03290908 | — | — | 0.770 |
| 3 | SRR12475169 | — | — | 0.768 |
| 4 | TCGA-CN-5355-01A-01R-1436-07 | — | — | 0.765 |
| 5 | SRR2932813 | — | — | 0.756 |
| 6 | BS_23QW0BBA | high-grade glioma | — | 0.748 |
| 7 | SRR8526723 | — | cohortA1 | 0.731 |
| 8 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.727 |
| 9 | MNG75 | — | — | 0.727 |
| 10 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |